Cigarette smoking and increased urine albumin excretion are interrelated predictors of nephropathy progression in type 2 diabetes

American Journal of Kidney Diseases

Volumn 41, Issue 1, 2003, Pages 13-21

  Chuahirun, Temduang ^a,b   Khanna, Apurv ^a,b   Kimball, Kay ^a,b   Wesson, Donald E ^a,b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

^b Statistical Design and Analysis   (United States)

Author keywords

Albuminuria; Blood pressure (BP); Cigarettes; End stage renal disease (ESRD); Hypertension; Kidney; Plasma creatinine (Pcr); Proteinuria; Renal failure; Smoking; Type 2 diabetes

Indexed keywords

CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HUMAN ALBUMIN;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CIGARETTE SMOKING; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DISEASE COURSE; DISEASE MARKER; ENZYME INHIBITION; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PROSPECTIVE STUDY; PROTEIN URINE LEVEL; PROTEINURIA; REGRESSION ANALYSIS; RISK FACTOR; URINARY EXCRETION;

EID: 0037223891     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2003.50009     Document Type: Article

References (38)

1. US Renal Data System: USRDS 2000 Annual Data Report. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2000
2. Bennett PH, Haffner S, Kasiske BL, et al: Screening and management of microalbuminuria in patients with diabetes mellitus. Recommendations to the Scientific Advisory Board of the National Kidney Foundation from an Ad Hoc Committee of the Council on Diabetes Mellitus of the National Kidney Foundation. Am J Kidney Dis 25:107-112, 1995
3. Lebovitz HE, Wiegmann TB, Cnaan A, et al: Renal protective effects of enalapril in hypertensive NIDDM: Role of baseline albuminuria. Kidney Int Suppl 45:S150-S155, 1994
4. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M: Long-term stabilizing effect of angiotensin converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 118:577-581, 1993
5. Yokoyama H, Tomonaga O, Hirayama M, et al: Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin converting enzyme inhibitors in NIDDM patients. Diabetologia 40:405-411, 1997
6. Chuahirun T, Wesson DE: Cigarette smoking predicts faster progression of type 2 established diabetic nephropathy despite angiotensin-converting enzyme inhibition. Am J Kidney Dis 39:376-382, 2002
7. Christiansen JS: Cigarette smoking and the prevalence of microangiopathy in juvenile-onset insulin-dependent diabetes mellitus. Diabetes Care 1:146-149, 1978
8. Muhlhauser I, Sawicki P, Berger M: Cigarette smoking as a risk factor for macroproteinuria and proliferative retinopathy in type 1 (insulin-dependent) diabetes. Diabetologia 29:500-502, 1986
9. Couper JJ, Staples AJ, Cocciolone R, Nairn J, Badcock N, Henning P: Relationship of smoking and albuminuria in children with insulin-dependent diabetes mellitus. Diabet Med 11:666-669, 1994
10. Sawicki PT, Didjurgeit U, Muhlhauser I, Bender R, Heinemann L, Berger M: Smoking is associated with progression of diabetic nephropathy. Diabetes Care 17:126-131, 1994
11. Joint National Commission on Detection, Evaluation, and Treatment of High Blood Pressure: The Fifth Report of The Joint National Commission on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 153:154-183, 1993
12. Klahr S, Levey AS, Beck GJ, et al, for the Modification of Diet in Renal Disease Study Group: The effects of dietary protein restriction and blood-pressure control on the progression chronic renal disease. N Engl J Med 330:877-884, 1994
13. Olivarius N de F, Andreasen AH, Keiding N, Mogensen CE: Epidemiology of renal involvement in newly-diagnosed middle-aged and elderly diabetic patients: Cross-sectional data from the population-based study "Diabetes Care in General Practice," Denmark. Diabetologia 36:1007-1016, 1993
14. Nielsen FS, Rossing P, Gall MA, Skott P, Smidt UM, Parving HH: Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 46:1182-1188, 1997
15. Perneger TV, Klag MJ, Feldman HI, Welton PK: Projections of hypertension-related renal disease in middle-aged residents of the United States. JAMA 269:1272-1277, 1993
16. UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulfonylreas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 352:837-853, 1998
17. Viberti GC, Bilous RW, Mackintosh D, Bending JJ, Keen H: Long term correction of hyperglycaemia and progression of renal failure in insulin dependent diabetes. BMJ 286:589-602, 1983
18. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41, 1976
19. Stata Corp: Stata User's Guide. Stata Statistical Software: Release 7.0. College Station, TX, Stata Corp, 2001
20. Burne MJ, Panagiotopoulos S, Jerums G, Comper WD: Alterations in the renal degradation of albumin in early experimental diabetes. Clin Sci 95:67-72, 1998
21. Mogensen CE: The kidney in diabetes: How to control renal and related cardiovascular complications. Am J Kidney Dis 37:S2-S6, 2001 (suppl 2)
22. Epstein M, Parving HH, Ruilope LM: Surrogate endpoints and renal protection: Focus on microalbuminuria. Blood Press Suppl 2:S52-S57, 1997
23. Adler S, Feld S, Striker L, et al: Glomerular type IV collagen in patients with diabetic nephropathy with and without additional glomerular disease. Kidney Int 57:2084-2092, 2000
24. Kohan DE: Endothelins in the normal and diseased kidney. Am J Kidney Dis 29:2-26, 1997
25. Mogyorosi A, Kapoor A, Isono M, Kapoor S, Sharam K, Ziyadeh FN: Utility of serum and urinary transforming growth factor beta levels as markers of diabetic nephropathy. Nephron 86:234-235, 2000
26. Ruiz-Ortega M, Gomez-Garre D, Alcazar R, et al: Involvement of angiotensin II and endothelin in matrix protein production and renal sclerosis. J Hypertens 12:S51-S58, 1994 (suppl 4)
27. Ziyadeh FN, Hoffman BB, Han DC, et al: Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db mice. Proc Natl Acad Sci U S A 97:8015-8020, 2000
28. Haak T, Jungmann E, Raab C, Usadel KH: Elevated endothelin-1 levels after cigarette smoking. Metabolism 43:267-269, 1994
29. Esmatjes E, Flores L, Lario S, et al: Smoking increases serum levels of transforming growth factor-beta in diabetic patients. Diabetes Care 22:1915-1916, 1999 (letter)
30. Cominacini L, Garbin U, Pastorino AM, Fratta-Pasisni A, Campagnola M, De Santis A: Increased susceptibility of LDL to in vitro oxidation in patients with IDDM and NIDDM. Diabetes Res 26:173-184, 1994
31. Obata T, Tomaru K, Nagakura T, Izumi Y, Kawamoto T: Smoking and oxidant stress: Assay of isoprostane in human urine by gas chromatography-mass spectrometry. J Chromatogr Biomed Sci Appl 746:11-15, 2000
32. Sundaram RK, Bhaskar A, Vijayalingam S, Viswanathan M, Mohan R, Shanmugasundaram KR: Antioxidant status and lipid peroxidation in type II diabetes mellitus with and without complications. Clin Sci 90:255-260, 1996
33. Mehrotra L, Ling KLE, Bekele Y, Gerbino E, Earle KA: Lidid hydroperoxide and markers of renal disease susceptibility in African-Caribbean and Caucasian patients with type 2 diabetes mellitus. Diabet Med 18:109-115, 2001
34. Chen H-C, Guh J-Y, Shin S-J, Tsai J-H, Lai Y-H: Reactive oxygen species enhances endothelin-1 production of diabetic rat glomeruli in vitro and in vivo. J Lab Clin Med 135:309-315, 2000
35. Reddi AS, Bollineni JS. Selenium-deficient diet induces renal oxidative stress and injury via TGF β1 in normal and diabetic rats. Kidney Int 59:1342-1353, 2001
36. Pinto-Sietsma S, Mulder J, Janssen W, Hillege H, deZeeuw D, de Jong P: Smoking is related to albuminuria and abnormal renal function in nondiabetic persons. Ann Intern Med 133:585-591, 2000
37. Lapena D, DeGioia S, Ciofani G, Daniele F, Cuccurullo F: Captopril has no significant scavenging antioxidant activity in human plasma in vitro or in vivo. Br J Clin Pharmacol 42:451-456, 1997
38. Ellis GR, Nightingale AK, Blackman DJ, et al: Addition of candesartin to angiotensin converting enzyme inhibitor therapy in patients with chronic heart failure does not reduce levels of oxidative stress. Eur J Heart Fail 4:193-199, 2002